BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30681723)

  • 1. From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK.
    Larose H; Burke GAA; Lowe EJ; Turner SD
    Br J Haematol; 2019 Jun; 185(6):1043-1054. PubMed ID: 30681723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.
    Wang X; Wu J; Zhang M
    Hematology; 2019 Dec; 24(1):440-445. PubMed ID: 31072226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
    Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
    Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic large cell lymphoma, ALK-negative.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients.
    Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY
    J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology and management of systemic anaplastic large cell lymphoma.
    Hapgood G; Savage KJ
    Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma.
    Shen J; Medeiros LJ; Li S; Wang SA; Lin P; Khanlari M; Iyer SP; Yin CC; Tang G; Jorgensen JL; Hu S; Miranda RN; Xu J
    Hum Pathol; 2020 Apr; 98():1-9. PubMed ID: 32032618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
    Shustov A; Soma L
    Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaplastic large cell lymphoma in paediatric and young adult patients.
    Turner SD; Lamant L; Kenner L; Brugières L
    Br J Haematol; 2016 May; 173(4):560-72. PubMed ID: 26913827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplastic lymphoma kinase proteins and malignancy.
    Pulford K; Morris SW; Mason DY
    Curr Opin Hematol; 2001 Jul; 8(4):231-6. PubMed ID: 11561161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
    Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
    Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
    Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
    J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells.
    Kuravi S; Cheng J; Fangman G; Polireddy K; McCormick S; Lin TL; Singh AK; Abhyankar S; Ganguly S; Welch DR; Jensen RA; McGuirk JP; Balusu R
    Mol Cancer Res; 2021 May; 19(5):913-920. PubMed ID: 33514657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
    Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
    Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma.
    Melchers RC; Willemze R; van de Loo M; van Doorn R; Jansen PM; Cleven AHG; Solleveld N; Bekkenk MW; van Kester MS; Diercks GFH; Vermeer MH; Quint KD
    Am J Surg Pathol; 2020 Jun; 44(6):776-781. PubMed ID: 32412717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma.
    Rajan SS; Amin AD; Li L; Rolland DC; Li H; Kwon D; Kweh MF; Arumov A; Roberts ER; Yan A; Basrur V; Elenitoba-Johnson KSJ; Chen XS; Puvvada SD; Lussier YA; Bilbao D; Lim MS; Schatz JH
    Oncogene; 2020 Mar; 39(10):2103-2117. PubMed ID: 31804622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 and β-Catenin Expression Predict Poorer Prognosis in Patients With Anaplastic Large-Cell Lymphoma.
    Richardson AI; Yin CC; Cui W; Li N; Medeiros LJ; Li L; Zhang D
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e385-e392. PubMed ID: 31078446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.
    ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Pulford K; Willemze R; Falini B; Chott A; Meijer CJ
    J Clin Pathol; 2000 Jun; 53(6):445-50. PubMed ID: 10911802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.